BioPlus Acquisition Overview
Valuation check: BIOS's ROE is 9.72%, above the sector sector average of -5.72%.
Get informed when a big investor buys or sells
+ Follow9.72%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BIOS is 9.72%. That is above the sector sector average of -5.72%. Investors often review this figure alongside BioPlus Acquisition's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, BIOS currently prints 9.72% for ROE, while the sector average sits near -5.72%. That is roughly 269.9% above the sector mean. Large gaps often invite a closer look at BioPlus Acquisition's growth, margins, and balance sheet.
Return on Equity shows how effectively BioPlus Acquisition converts resources into returns. At 9.72%, BIOS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BIOS's ROE (9.72%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
